Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders

Progress in Brain Research

Volumn 172, Issue , 2008, Pages 423-463

  Di Matteo, Vincenzo ^a   Pierucci, Massimo ^a   Esposito, Ennio ^a   Crescimanno, Giuseppe ^b   Benigno, Arcangelo ^b   Di Giovanni, Giuseppe ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

basal ganglia; dyskinesia; motor disorders; Parkinson's disease; selective 5 HT drugs; serotonergic receptors

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 [3 FLUORO 5 (3 PYRIDYL)PHENYLCARBAMOYL] 5 METHOXY 6 TRIFLUOROMETHYLINDOLINE; 1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; 3 (3 DIMETHYLAMINOPROPYL) 4 HYDROXY N [4 (4 PYRIDINYL)PHENYL]BENZAMIDE; 4 AMINOBUTYRIC ACID RECEPTOR; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL] 6 TRIFLUOROMETHYLINDOLINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8 [5 [2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLPHENYLSULFONAMIDO)PHENYL] 5 OXOPENTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; AMITRIPTYLINE; BENSERAZIDE; BICUCULLINE; CLOMIPRAMINE; CLOZAPINE; DOXEPIN; FLUOXETINE; KETANSERIN; LEVODOPA; METERGOLINE; MIANSERIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RITANSERIN; SB 23597 190; SEROTONIN; SEROTONIN ANTAGONIST; SSR 181507; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLINANSERIN;

AKATHISIA; BASAL GANGLION; BINDING SITE; BRAIN DEPTH STIMULATION; CATALEPSY; CORPUS STRIATUM; DORSAL RAPHE NUCLEUS; DYSKINESIA; DYSTONIA; EXCITATORY POSTSYNAPTIC POTENTIAL; GLOBUS PALLIDUS; HUMAN; IMMUNOREACTIVITY; MEDIAN RAPHE NUCLEUS; MOTOR CONTROL; MOTOR DYSFUNCTION; NERVE CELL NETWORK; NONHUMAN; PARKINSON DISEASE; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PRIORITY JOURNAL; PSEUDOPARKINSONISM; RAPHE MAGNUS NUCLEUS; REVIEW; SUBSTANTIA NIGRA; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; MOVEMENT DISORDERS; NEURAL PATHWAYS; PARKINSON DISEASE; PROTEIN ISOFORMS; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS;

EID: 50649111180     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)00921-7     Document Type: Review

References (344)

1. Abi-Dargham A., Laruelle M., Wong D.T., Robertson D.W., Weinberger D.R., and Kleinman J.E. Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J. Neurochem. 60 2 (1993) 730-737
2. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12 10 (1989) 366-375
3. Altar C.A., Wasley A.M., Neale R.F., and Stone G.A. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res. Bull. 16 4 (1986) 517-525
4. Antonelli T., Fuxe K., Tomasini M.C., Bartoszyk G.D., Seyfried C.A., Tanganelli S., and Ferraro L. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58 3 (2005) 193-199
5. Avila A., Cardona X., Martin-Baranera M., Maho P., Sastre F., and Bello J. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J. Clin. Psychopharmacol. 23 5 (2003) 509-513
6. Azmitia E.C., and Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol. 179 3 (1978) 641-667
7. Balcioglu A., Zhang K., and Tarazi F.I. Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study. Neuroscience 119 4 (2003) 1045-1053
8. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Can. Med. Assoc. J. 87 (1962) 802-807
9. Barnes J.M., Barnes N.M., Champaneria S., Costall B., and Naylor R.J. Characterisation and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat. Neuropharmacology 29 11 (1990) 1037-1045
10. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 8 (1999) 1083-1152
11. Bartoszyk G.D., Roos C., and Ziegler H. 5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential. Neuropharmacology 35 11 (1996) 1645-1646
12. Barwick V.S., Jones D.H., Richter J.T., Hicks P.B., and Young K.A. Subthalamic nucleus microinjections of 5-HT2 receptor antagonists suppress stereotypy in rats. Neuroreport 11 2 (2000) 267-270
13. Basura G.J., and Walker P.D. Serotonin 2A receptor mRNA levels in the neonatal dopamine-depleted rat striatum remain upregulated following suppression of serotonin hyperinnervation. Brain Res. Dev. Brain Res. 116 1 (1999) 111-117
14. Basura G.J., and Walker P.D. Serotonin 2A receptor regulation of striatal neuropeptide gene expression is selective for tachykinin, but not enkephalin neurons following dopamine depletion. Brain Res. Mol. Brain Res. 92 1-2 (2001) 66-77
15. Bata-Garcia J.L., Heredia-Lopez F.J., Alvarez-Cervera F.J., Arankowsky-Sandoval G., and Gongora-Alfaro J.L. Circling behavior induced by microinjection of serotonin reuptake inhibitors in the substantia nigra. Pharmacol. Biochem. Behav. 71 1-2 (2002) 353-363
16. Belforte J.E., and Pazo J.H. Turning behaviour induced by stimulation of the 5-HT receptors in the subthalamic nucleus. Eur. J. Neurosci. 19 2 (2004) 346-355
17. Bengtson C.P., Lee D.J., and Osborne P.B. Opposing electrophysiological actions of 5-HT on noncholinergic and cholinergic neurons in the rat ventral pallidum in vitro. J. Neurophysiol. 92 1 (2004) 433-443
18. Bersani G., Grispini A., Marini S., Pasini A., Valducci M., and Ciani N. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin. Neuropharmacol. 13 6 (1990) 500-506
19. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2 8 (2001) 577-588
20. Bezard E., Gerlach I., Moratalla R., Gross C.E., and Jork R. 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol. Dis. 23 1 (2006) 77-86
21. Bezard E., Gross C.E., and Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26 4 (2003) 215-221
22. Bharucha K.J., and Sethi K.D. Complex movement disorders induced by fluoxetine. Mov. Disord. 11 3 (1996) 324-326
23. Bhidayasiri R., and Truong D.D. Chorea and related disorders. Postgrad. Med. J. 80 947 (2004) 527-534
24. Birkmayer W., and Birkmayer J.D. Dopamine action and disorders of neurotransmitter balance. Gerontology 33 3-4 (1987) 168-171
25. Birkmayer W., and Riederer P. Biological aspects of depression in Parkinson's disease. Psychopathology 19 2 (1986) 58-61
26. Bishop C., Daut G.S., and Walker P.D. Serotonin 5-HT2A but not 5-HT2C receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D1 agonist SKF 82958. Neuropharmacology 49 3 (2005) 350-358
27. Bishop C., Tessmer J.L., Ullrich T., Rice K.C., and Walker P.D. Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism. J. Pharmacol. Exp. Ther. 310 2 (2004) 687-694
28. Blackburn T.P. Serotonergic agents and Parkinson's disease. Drug Discov. Today Ther. Strateg. 1 (2004) 35-41
29. Blackburn T.P., Cox B., Heapy C.G., Lee T.F., and Middlemiss D.N. Supersensitivity of nigral serotonin receptors and rat rotational behaviour. Eur. J. Pharmacol. 71 2-3 (1981) 343-346
30. Blackburn T.P., Kemp J.D., Martin D.A., and Cox B. Evidence that 5-HT agonist-induced rotational behaviour in the rat is mediated via 5-HT1 receptors. Psychopharmacology (Berl.) 83 2 (1984) 163-165
31. Blomeley C., and Bracci E. Excitatory effects of serotonin on rat striatal cholinergic interneurones. J. Physiol. (Lond.) 569 Pt 3 (2005) 715-721
32. Blurton P.A., and Wood M.D. Identification of multiple binding sites for [3H]5-hydroxytryptamine in the rat CNS. J. Neurochem. 46 5 (1986) 1392-1398
33. Boess F.G., and Martin I.L. Molecular biology of 5-HT receptors. Neuropharmacology 33 3-4 (1994) 275-317
34. Bonaventure P., Hall H., Gommeren W., Cras P., Langlois X., Jurzak M., and Leysen J.E. Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse 36 1 (2000) 35-46
35. Bonaventure P., Voorn P., Luyten W.H., Jurzak M., Schotte A., and Leysen J.E. Detailed mapping of serotonin 5-HT1B and 5-HT1D receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function. Neuroscience 82 2 (1998) 469-484
36. Bonsi P., Cuomo D., Ding J., Sciamanna G., Ulrich S., Tscherter A., Bernardi G., Surmeier D.J., and Pisani A. Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 32 8 (2007) 1840-1854
37. Bonsi P., Cuomo D., Picconi B., Sciamanna G., Tscherter A., Tolu M., Bernardi G., Calabresi P., and Pisani A. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease. Amino Acids 32 2 (2007) 189-195
38. Boschert U., Amara D.A., Segu L., and Hen R. The mouse 5-hydroxytryptamine1B receptor is localized predominantly on axon terminals. Neuroscience 58 1 (1994) 167-182
39. Bourson A., Boess F.G., Bös M., and Sleight A.J. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br. J. Pharmacol. 125 7 (1998) 1562-1566
40. Breese G.R., Baumeister A., Napier T.C., Frye G.D., and Mueller R.A. Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 235 2 (1985) 287-295
41. Breese G.R., Knapp D.J., Criswell H.E., Moy S.S., Papadeas S.T., and Blake B.L. The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles. Brain Res. Brain Res. Rev. 48 1 (2005) 57-73
42. Brodie B.B., Pletscher A., and Shore P.A. Evidence that serotonin has a role in brain function. Science 122 3177 (1955) 968
43. Brown P., and Gerfen C.R. Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 map kinase pathway. J. Comp. Neurol. 498 3 (2006) 415-430
44. Bruggeman R., Heeringa M., Westerink B.H., and Timmerman W. Combined 5-HT2/D2 receptor blockade inhibits the firing rate of SNR neurons in the rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry 24 4 (2000) 579-593
45. Bruinvels A.T., Landwehrmeyer B., Gustafson E.L., Durkin M.M., Mengod G., Branchek T.A., Hoyer D., and Palacios J.M. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 33 3-4 (1994) 367-386
46. Bruinvels A.T., Palacios J.M., and Hoyer D. Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 347 6 (1993) 569-582
47. Bruinvels A.T., Palacios J.M., and Hoyer D. 5-hydroxytryptamine1 recognition sites in rat brain: heterogeneity of non-5-hydroxytryptamine1A/1C binding sites revealed by quantitative receptor autoradiography. Neuroscience 53 2 (1993) 465-473
48. Bubser M., Backstrom J.R., Sanders-Bush E., Roth B.L., and Deutch A.Y. Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum. Synapse 39 4 (2001) 297-304
49. Bufton K.E., Steward L.J., Barber P.C., and Barnes N.M. Distribution and characterization of the [3H]granisetron-labelled 5-HT3 receptor in the human forebrain. Neuropharmacology 32 12 (1993) 1325-1331
50. Bymaster F.P., Falcone J.F., Bauzon D., Kennedy J.S., Schenck K., DeLapp N.W., and Cohen M.L. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur. J. Pharmacol. 430 2-3 (2001) 341-349
51. Canton H., Verriele L., and Colpaert F.C. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. Eur. J. Pharmacol. 191 1 (1990) 93-96
52. Canton H., Verriele L., and Millan M.J. Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci. Lett. 181 1-2 (1994) 65-68
53. Carlson B.B., Wisniecki A., and Salamone J.D. Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of parkinsonian tremor. Psychopharmacology (Berl.) 165 3 (2003) 229-237
54. Carlsson T., Carta M., Winkler C., Bjorklund A., and Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 27 30 (2007) 8011-8022
55. Carta M., Carlsson T., Kirik D., and Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130 Pt 7 (2007) 1819-1833
56. Castro M.E., Pascual J., Romon T., Berciano J., Figols J., and Pazos A. 5-HT1B receptor binding in degenerative movement disorders. Brain Res. 790 1-2 (1998) 323-328
57. Chadha A., Sur C., Atack J., and Duty S. The 5HT(1B) receptor agonist, CP-93129, inhibits [(3)H]-GABA release from rat globus pallidus slices and reverses akinesia following intrapallidal injection in the reserpine-treated rat. Br. J. Pharmacol. 130 8 (2000) 1927-1932
58. Charles P.D., Padaliya B.B., Newman W.J., Gill C.E., Covington C.D., Fang J.Y., So S.A., Tramontana M.G., Konrad P.E., and Davis T.L. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat. Disord. 10 8 (2004) 475-479
59. Chase T.N. Serotonergic-dopaminergic interactions and extrapyramidal function. Adv. Biochem. Psychopharmacol. 11 (1974) 377-385
60. Chase T.N., and Ng L.K. Central monoamine metabolism in Parkinson's disease. Arch. Neurol. 27 6 (1972) 486-491
61. Chen L., Yung K.K., Chan Y.S., and Yung W.H. 5-HT excites globus pallidus neurons by multiple receptor mechanisms. Neuroscience 151 2 (2008) 439-451
62. Chinaglia G., Landwehrmeyer B., Probst A., and Palacios J.M. Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 54 3 (1993) 691-699
63. Chu Y.X., Liu J., Feng J., Wang Y., Zhang Q.J., and Li Q. [Changes of discharge rate and pattern of 5-hydroxytrypamine neurons of dorsal raphe nucleus in a rat model of Parkinson's disease]. Sheng Li Xue Bao 56 5 (2004) 597-602
64. Cicin-Sain L., and Jenner P. Reduction in cortical 5-HT3 binding sites following a unilateral 6-hydroxydopamine lesion of the medial forebrain bundle in rats. J. Neurol. Sci. 115 1 (1993) 105-110
65. Clayton A.H. Antidepressant-induced tardive dyskinesia: review and case report. Psychopharmacol. Bull. 31 2 (1995) 259-264
66. Collingridge G.L., and Davies J. The influence of striatal stimulation and putative neurotransmitters on identified neurones in the rat substantia nigra. Brain Res. 212 2 (1981) 345-359
67. Commins D.L., Shaughnessy R.A., Axt K.J., Vosmer G., and Seiden L.S. Variability among brain regions in the specificity of 6-hydroxydopamine (6-OHDA)-induced lesions. J. Neural Transm. 77 2-3 (1989) 197-210
68. Compan V., Daszuta A., Salin P., Sebben M., Bockaert J., and Dumuis A. Lesion study of the distribution of serotonin 5-HT4 receptors in rat basal ganglia and hippocampus. Eur. J. Neurosci. 8 12 (1996) 2591-2598
69. Compan V., Segu L., Buhot M.C., and Daszuta A. Selective increases in serotonin 5-HT1B/1D and 5-HT2A/2C binding sites in adult rat basal ganglia following lesions of serotonergic neurons. Brain Res. 793 1-2 (1998) 103-111
70. Cornea-Hébert V., Riad M., Wu C., Singh S.K., and Descarries L. Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J. Comp. Neurol. 409 2 (1999) 187-209
71. Corvaja N., Doucet G., and Bolam J.P. Ultrastructure and synaptic targets of the raphe-nigral projection in the rat. Neuroscience 55 2 (1993) 417-427
72. D'Addario C., Di Benedetto M., Izenwasser S., Candeletti S., and Romualdi P. Role of serotonin in the regulation of the dynorphinergic system by a kappa-opioid agonist and cocaine treatment in rat CNS. Neuroscience 144 1 (2007) 157-164
73. Dahlström A., and Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol. Scand. 62 232 (1964) 1-55
74. Darmani N.A., Shaddy J., and Gerdes C.F. Differential ontogenesis of three DOI-induced behaviors in mice. Physiol. Behav. 60 6 (1996) 1495-1500
75. Davies J., and Tongroach P. Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat. Eur. J. Pharmacol. 51 2 (1978) 91-100
76. De Deurwaerdere P., and Chesselet M.F. Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats. J. Neurosci. 20 13 (2000) 5170-5178
77. del Arco C., Galende I., and Pazos A. Autoradiographic mapping of 5-HT1 receptors in the guinea-pig brain with particular reference to the 5-HT1D receptor sites. Naunyn Schmiedebergs Arch. Pharmacol. 347 3 (1993) 248-256
78. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13 7 (1990) 281-285
79. Deniau J.M., and Chevalier G. Disinhibition as a basic process in the expression of striatal functions. II. The striato-nigral influence on thalamocortical cells of the ventromedial thalamic nucleus. Brain Res. 334 2 (1985) 227-233
80. Di Giovanni G. Will it ever become possible to prevent dopaminergic neuronal degeneration?. CNS Neurol. Disord. Drug Targets 7 1 (2008) 28-44
81. Di Giovanni G., Di Matteo V., La Grutta V., and Esposito E. m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors. Neuroscience 103 1 (2001) 111-116
82. Di Giovanni G., Di Matteo V., Pierucci M., Benigno A., and Esposito E. Central serotonin2C receptor: from physiology to pathology. Curr. Top. Med. Chem. 6 18 (2006) 1909-1925
83. Di Giovanni G., Di Matteo V., Pierucci M., Benigno A., and Esposito E. Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?. Curr. Med. Chem. 13 25 (2006) 3069-3081
84. Dijk S.N., Francis P.T., Stratmann G.C., and Bowen D.M. NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist. Br. J. Pharmacol. 115 7 (1995) 1169-1174
85. Di Matteo V., Cacchio M., Di Giulio C., Di Giovanni G., and Esposito E. Biochemical evidence that the atypical antipsychotic drugs clozapine and risperidone block 5-HT(2C) receptors in vivo. Pharmacol. Biochem. Behav. 71 4 (2002) 607-613
86. Doder M., Rabiner E.A., Turjanski N., Lees A.J., and Brooks D.J. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60 4 (2003) 601-605
87. Doucet E., Miquel M.C., Nosjean A., Verge D., Hamon M., and Emerit M.B. Immunolabeling of the rat central nervous system with antibodies partially selective of the short form of the 5-HT3 receptor. Neuroscience 95 3 (1999) 881-892
88. Dray A., Gonye T.J., and Oakley N.R. Effects of alpha-flupenthixol on dopamine and 5-hydroxytryptamine responses of substantia nigra neurones. Neuropharmacology 15 12 (1976) 793-796
89. Duncan G.E., Knapp D.J., Breese G.R., Crews F.T., and Little K.Y. Species differences in regional patterns of 3H-8-OH-DPAT and 3H-zolpidem binding in the rat and human brain. Pharmacol. Biochem. Behav. 60 2 (1998) 439-448
90. Durif F., Debilly B., Galitzky M., Morand D., Viallet F., Borg M., Thobois S., Broussolle E., and Rascol O. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62 3 (2004) 381-388
91. Duvoisin R.C. Cholinergic-anticholinergic antagonism in parkinsonism. Arch. Neurol. 17 2 (1967) 124-136
92. Eberle-Wang K., Lucki I., and Chesselet M.F. A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 72 1 (1996) 117-128
93. Eberle-Wang K., Mikeladze Z., Uryu K., and Chesselet M.F. Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J. Comp. Neurol. 384 2 (1997) 233-247
94. Eisensamer B., Uhr M., Meyr S., Gimpl G., Deiml T., Rammes G., Lambert J.J., Zieglgansberger W., Holsboer F., and Rupprecht R. Antidepressants and antipsychotic drugs colocalize with 5-HT3 receptors in raft-like domains. J. Neurosci. 25 44 (2005) 10198-10206
95. Ellison G. Spontaneous orofacial movements in rodents induced by long-term neuroleptic administration: a second opinion. Psychopharmacology (Berl.) 104 3 (1991) 404-408
96. Ellison G., and See R.E. Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia. Psychopharmacology (Berl.) 98 4 (1989) 564-566
97. el Mansari M., and Blier P. In vivo electrophysiological characterization of 5-HT receptors in the guinea pig head of caudate nucleus and orbitofrontal cortex. Neuropharmacology 36 4-5 (1997) 577-588
98. el Mansari M., Radja F., Ferron A., Reader T.A., Molina-Holgado E., and Descarries L. Hypersensitivity to serotonin and its agonists in serotonin-hyperinnervated neostriatum after neonatal dopamine denervation. Eur. J. Pharmacol. 261 1-2 (1994) 171-178
99. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., and Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 205 2 (2007) 295-312
100. Esposito E., Di Matteo V., and Di Giovanni G. Death in the substantia nigra: a motor tragedy. Expert Rev. Neurother. 7 6 (2007) 677-697
101. Esposito E., Di Matteo V., Pierucci M., Benigno A., and Di Giovanni G. Role of central 5-ht2c receptor in the control of basal ganglia functions. In: Di Giovanni G. (Ed). The basal ganglia pathophysiology: recent advances (2007), Transworld Research Network, Trivandrum 97-127
102. Fibiger H.C., and Miller J.J. An anatomical and electrophysiological investigation of the serotoninergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 2 (1977) 975-987
103. Filip M., Bubar M.J., and Cunningham K.A. Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J. Pharmacol. Exp. Ther. 310 3 (2004) 1246-1254
104. Filip M., and Cunningham K.A. Serotonin 5-HT(2C) receptors in nucleus accumbens regulate expression of the hyperlocomotive and discriminative stimulus effects of cocaine. Pharmacol. Biochem. Behav. 71 4 (2002) 745-756
105. Fletcher P.J., Grottick A.J., and Higgins G.A. Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 27 4 (2002) 576-586
106. Fletcher S., and Barnes N.M. Autoradiographic localization of the [3H]-(S)-zacopride labelled 5-HT3 receptor in porcine brain. Neurosci. Lett. 269 2 (1999) 91-94
107. Flores G., Rosales M.G., Hernandez S., Sierra A., and Aceves J. 5-Hydroxytryptamine increases spontaneous activity of subthalamic neurons in the rat. Neurosci. Lett. 192 1 (1995) 17-20
108. Fox S.H., and Brotchie J.M. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur. J. Pharmacol. 398 1 (2000) 59-64
109. Fox S.H., and Brotchie J.M. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord. 15 6 (2000) 1064-1069
110. Fox S.H., Moser B., and Brotchie J.M. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151 1 (1998) 35-49
111. 1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39 4 (2001) 288-296
112. Garcia L., D'Alessandro G., Bioulac B., and Hammond C. High-frequency stimulation in Parkinson's disease: more or less?. Trends Neurosci. 28 4 (2005) 209-216
113. Gardell L.R., Vanover K.E., Pounds L., Johnson R.W., Barido R., Anderson G.T., Veinbergs I., Dyssegaard A., Brunmark P., Tabatabaei A., Davis R.E., Brann M.R., Hacksell U., and Bonhaus D.W. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J. Pharmacol. Exp. Ther. 322 2 (2007) 862-870
114. Gehlert D.R., Gackenheimer S.L., Wong D.T., and Robertson D.W. Localization of 5-HT3 receptors in the rat brain using [3H]LY278584. Brain Res. 553 1 (1991) 149-154
115. Gehlert D.R., Schober D.A., Gackenheimer S.L., Mais D.E., Ladouceur G., and Robertson D.W. Synthesis and evaluation of [125I]-(S)-iodozacopride, a high affinity radioligand for 5HT3 receptors. Neurochem. Int. 23 4 (1993) 373-383
116. 6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 23 3 (1996) 164-173
117. 6 receptor-like material in the rat central nervous system. Brain Res. 746 1-2 (1997) 207-219
118. Gerber R., Altar C.A., and Liebman J.M. Rotational behavior induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl.) 94 2 (1988) 178-182
119. Gerfen C.R. The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature 311 5985 (1984) 461-464
120. Gerfen C.R. The neostriatal mosaic. I. Compartmental organization of projections from the striatum to the substantia nigra in the rat. J. Comp. Neurol. 236 4 (1985) 454-476
121. Goldstein M., Anagnoste B., Battista A.F., Owen W.S., and Nakatani S. Studies of amines in the striatum in monkeys with nigral lesions. The disposition, biosynthesis and metabolites of [3H]dopamine and [14C]serotonin in the striatum. J. Neurochem. 16 4 (1969) 645-653
122. Gong L., and Kostrzewa R.M. Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats. Pharmacol. Biochem. Behav. 41 3 (1992) 621-623
123. Gongora-Alfaro J.L., Hernandez-Lopez S., Flores-Hernandez J., and Galarraga E. Firing frequency modulation of substantia nigra reticulata neurons by 5-hydroxytryptamine. Neurosci. Res. 29 3 (1997) 225-231
124. Granoff M.I., and Ashby Jr. C.R. The effect of the repeated administration of the compound 3,4-methylenedioxymethamphetamine on the response of rats to the 5-HT2A,C receptor agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Neuropsychobiology 37 1 (1998) 36-40
125. (2C) receptors on cocaine- and food-maintained behavior. J. Pharmacol. Exp. Ther. 295 3 (2000) 1183-1191
126. Guerra M.J., Liste I., and Labandeira-Garcia J.L. Effects of lesions of the nigrostriatal pathway and of nigral grafts on striatal serotonergic innervation in adult rats. Neuroreport 8 16 (1997) 3485-3488
127. Guiard B.P., el Mansari M., Merali Z., and Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int. J. Neuropsychopharmacol. 21 (2008) 1-15
128. Gunes A., Dahl M.-L., Spina E., and Scordo M. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur. J. Clin. Pharmacol. 64 5 (2008) 477-482
129. Gunes A., Scordo M., Jaanson P., and Dahl M.-L. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology (Berl.) 190 4 (2007) 479-484
130. Haapaniemi T.H., Ahonen A., Torniainen P., Sotaniemi K.A., and Myllyla V.V. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov. Disord. 16 1 (2001) 124-130
131. Haleem D.J., and Khan N.H. Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 4 (2003) 645-651
132. Haleem D.J., Samad N., and Haleem M.A. Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study. Behav. Pharmacol. 18 2 (2007) 147-153
133. Haleem D.J., Samad N., and Haleem M.A. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Pharmacol. Biochem. Behav. 87 1 (2007) 115-121
134. Haleem D.J., Shireen E., and Haleem M.A. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 8 (2004) 1323-1329
135. Hall H., Lundkvist C., Halldin C., Farde L., Pike V.W., McCarron J.A., Fletcher A., Cliffe I.A., Barf T., Wikstrom H., and Sedvall G. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res. 745 1-2 (1997) 96-108
136. Halliday G.M., Blumbergs P.C., Cotton R.G.H., Blessing W.W., and Geffen L.B. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res. 510 1 (1990) 104-107
137. Hameleers R., Blokland A., Steinbusch H.W.M., Visser-Vandewalle V., and Temel Y. Hypomobility after DOI administration can be reversed by subthalamic nucleus deep brain stimulation. Behav. Brain Res. 185 1 (2007) 65-67
138. 6 receptors. Neuropsychopharmacology 21 2 Suppl (1999) 68S-76S
139. Hashimoto K., and Kita H. Serotonin activates presynaptic and postsynaptic receptors in rat globus pallidus. J. Neurophysiol. 99 4 (2008) 1723-1732
140. Hawkins M.F., Uzelac S.M., Baumeister A.A., Hearn J.K., Broussard J.I., and Guillot T.S. Behavioral responses to stress following central and peripheral injection of the 5-HT2 agonist DOI. Pharmacol. Biochem. Behav. 73 3 (2002) 537-544
141. 2C receptors. J. Pharmacol. Exp. Ther. 295 1 (2000) 226-232
142. Hervé D., Pickel V.M., Joh T.H., and Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 435 1-2 (1987) 71-83
143. Hicks P.B. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci. 47 18 (1990) 1609-1615
144. 1D receptors in the substantia nigra of the guinea-pig elicits contralateral rotation. Br. J. Pharmacol. 102 2 (1991) 305-310
145. Hirst W.D., Abrahamsen B., Blaney F.E., Calver A.R., Aloj L., Price G.W., and Medhurst A.D. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol. Pharmacol 64 (2003) 1295-1308
146. Hirst W.D., Minton J.A., Bromidge S.M., Moss S.F., Latter A.J., Riley G., Routledge C., Middlemiss D.N., and Price G.W. Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. Br. J. Pharmacol. 130 7 (2000) 1597-1605
147. Hoffman B.J., and Mezey E. Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. FEBS Lett. 247 2 (1989) 453-462
148. Horner K.A., Adams D.H., Hanson G.R., and Keefe K.A. Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion. Neuroscience 131 1 (2005) 67-77
149. Hornykiewicz O. Dopamine in the basal ganglia: its role and therapeutic implications (including the clinical use of L-DOPA). Br. Med. Bull. 29 2 (1973) 172-178
150. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 51 2 (1998) S2-S9
151. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71 4 (2002) 533-554
152. Hoyer D., Pazos A., Probst A., and Palacios J.M. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res. 376 1 (1986) 85-96
153. Ikeguchi K., and Kuroda A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur. Arch. Psychiatry Clin. Neurosci. 244 6 (1995) 320-324
154. Ikram H., Samad N., and Haleem D.J. Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia. Pak. J. Pharm. Sci. 20 3 (2007) 188-195
155. Invernizzi R.W., Cervo L., and Samanin R. 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 27 5 (1988) 515-518
156. Invernizzi R.W., Pierucci M., Calcagno E., Di Giovanni G., Di Matteo V., Benigno A., and Esposito E. Selective activation of 5-HT2C receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study. Neuroscience 144 4 (2007) 1523-1535
157. Ito H., Halldin C., and Farde L. Localization of 5-HT1A receptors in the living human brain using [carbonyl-11C]WAY-100635: PET with anatomic standardization technique. J. Nucl. Med. 40 1 (1999) 102-109
158. Jackson M.J., Al-Barghouthy G., Pearce R.K.B., Smith L., Hagan J.J., and Jenner P. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol. Biochem. Behav. 79 3 (2004) 391-400
159. Jacobs B.L., and Azmitia E.C. Structure and function of the brain serotonin system. Physiol. Rev. 72 1 (1992) 165-229
160. James T.A., and Starr M.S. Rotational behaviour elicited by 5-HT in the rat: evidence for an inhibitory role of 5-HT in the substantia nigra and corpus striatum. J. Pharm. Pharmacol. 32 3 (1980) 196-200
161. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv. Neurol. 45 (1987) 1-18
162. B synaptic potential in rat dopamine neurons. J. Neurosci. 12 5 (1992) 2000-2006
163. Johnston T.H., and Brotchie J.M. Drugs in development for Parkinson's disease: an update. Curr. Opin. Investig. Drugs 7 1 (2006) 25-32
164. Kalkman H.O., Neumann V., and Tricklebank M.D. Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn Schmiedebergs Arch. Pharmacol. 355 3 (1997) 361-364
165. Kehne J.H., Ketteler H.J., McCloskey T.C., Sullivan C.K., Dudley M.W., and Schmidt C.J. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15 2 (1996) 116-124
166. Kennett G.A., Lightowler S., de Biasi V., Stevens N.C., Wood M.D., Tulloch I.F., and Blackburn T.P. Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 33 12 (1994) 1581-1588
167. Kennett G.A., Wood M.D., Bright F., Cilia J., Piper D.C., Gager T., Thomas D., Baxter G.S., Forbes I.T., Ham P., and Blackburn T.P. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmacol. 117 3 (1996) 427-434
168. Kennett G.A., Wood M.D., Bright F., Trail B., Riley G., Holland V., Avenell K.Y., Stean T., Upton N., Bromidge S., Forbes I.T., Brown A.M., Middlemiss D.N., and Blackburn T.P. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36 4-5 (1997) 609-620
169. Kerenyi L., Ricaurte G.A., Schretlen D.J., McCann U., Varga J., Mathews W.B., Ravert H.T., Dannals R.F., Hilton J., Wong D.F., and Szabo Z. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch. Neurol. 60 9 (2003) 1223-1229
170. Khawaja X. Quantitative autoradiographic characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist. Brain Res. 673 2 (1995) 217-225
171. Kienzl E., Riederer P., Jellinger K., and Wesemann W. Transitional states of central serotonin receptors in Parkinson's disease. J. Neural. Transm. 51 1-2 (1981) 113-122
172. Kim S.E., Choi J.Y., Choe Y.S., Choi Y., and Lee W.Y. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-{beta}-CIT SPECT. J. Nucl. Med. 44 6 (2003) 870-876
173. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.-J., Guttman M., and Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 131 1 (2008) 120-131
174. Kita H., Chiken S., Tachibana Y., and Nambu A. Serotonin modulates pallidal neuronal activity in the awake monkey. J. Neurosci. 27 1 (2007) 75-83
175. Kita H., and Kitai S.T. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J. Comp. Neurol. 260 3 (1987) 435-452
176. Kleven M.S., Barret-Grevoz C., Slot L.B., and Newman-Tancredi A. Novel antipsychotic agents with 5-HT1A agonist properties: Role of 5-HT1A receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49 2 (2005) 135-143
177. Knobelman D.A., Kung H.F., and Lucki I. Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT1A and 5-HT1B receptors. J. Pharmacol. Exp. Ther. 292 3 (2000) 1111-1117
178. Kohen R., Metcalf M.A., Khan N., Druck T., Huebner K., Lachowicz J.E., Meltzer H.Y., Sibley D.R., Roth B.L., and Hamblin M.W. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem. 66 1 (1996) 47-56
179. Krack P., Batir A., Van Blercom N., Chabardes S., Fraix V., Ardouin C., Koudsie A., Limousin P.D., Benazzouz A., LeBas J.F., Benabid A.-L., and Pollak P. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 349 20 (2003) 1925-1934
180. Krack P., Benazzouz A., Pollak P., Limousin P., Piallat B., Hoffmann D., Xie J., and Benabid A.L. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov. Disord. 13 6 (1998) 907-914
181. Krebs-Thomson K., and Geyer M.A. The role of 5-HT(1A) receptors in the locomotor-suppressant effects of LSD: WAY-100635 studies of 8-OH-DPAT, DOI and LSD in rats. Behav. Pharmacol. 7 6 (1996) 551-559
182. Kung M.P., Frederick D., Mu M., Zhuang Z.P., and Kung H.F. 4-(2′-Methoxy-phenyl)-1-[2′-(n-2″-pyridinyl)-p-iodoben zamido]-ethyl-piperazine ([125I]p-MPPI) as a new selective radioligand of serotonin-1A sites in rat brain: in vitro binding and autoradiographic studies. J. Pharmacol. Exp. Ther. 272 1 (1995) 429-437
183. Kuoppamaki M., Palvimaki E.P., Hietala J., and Syvalahti E. Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 13 2 (1995) 139-150
184. Kuoppamaki M., Syvalahti E., and Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur. J. Pharmacol. 245 2 (1993) 179-182
185. 1H]zacopride as radioligands. Synapse 10 4 (1992) 271-281
186. Laprade N., Radja F., Reader T.A., and Soghomonian J.-J. Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons. J. Neurosci. 16 11 (1996) 3727-3736
187. Lavoie B., and Parent A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J. Comp. Neurol. 299 1 (1990) 1-16
188. Lee M.S., Rinne J.O., and Marsden C.D. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med. J. 41 2 (2000) 167-184
189. Leentjens A.F.G. Depression in Parkinson's disease: conceptual issues and clinical challenges. J. Geriat. Psychiatr. Neurol. 17 3 (2004) 120-126
190. Leentjens A.F.G., Scholtissen B., Vreeling F.W., and Verhey F.R.J. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology 31 5 (2006) 1009-1015
191. Leysen J.E., Gommeren W., Van Gompel P., Wynants J., Janssen P.F., and Laduron P.M. Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol. Pharmacol. 27 6 (1985) 600-611
192. Limousin P., Pollak P., Benazzouz A., Hoffmann D., Le Bas J.F., Broussolle E., Perret J.E., and Benabid A.L. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345 8942 (1995) 91-95
193. Lopez-Gimenez J.F., Mengod G., Palacios J.M., and Vilaro M.T. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907. Naunyn Schmiedebergs Arch. Pharmacol. 356 4 (1997) 446-454
194. Lopez-Gimenez J.F., Mengod G., Palacios J.M., and Vilaro M.T. Human striosomes are enriched in 5-HT2A receptors: autoradiographical visualization with [3H]MDL100,907, [125I](±)DOI and [3H]ketanserin. Eur. J. Neurosci. 11 10 (1999) 3761-3765
195. Lucas G., Bonhomme N., Deurwaerdère P.D., Moal M.L., and Spampinato U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology (Berl.) 131 1 (1997) 57-63
196. Lucas G., De Deurwaerdère P., Caccia S., and Umberto S. The effect of serotonergic agents on haloperidol-induced striatal dopamine release in vivo: opposite role of 5-HT2A and 5-HT2C receptor subtypes and significance of the haloperidol dose used. Neuropharmacology 39 6 (2000) 1053-1063
197. Maeda T., Kannari K., Shen H., Arai A., Tomiyama M., Matsunaga M., and Suda T. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci. Lett. 343 1 (2003) 17-20
198. Mailly P., Charpier S., Menetrey A., and Deniau J.-M. Three-dimensional organization of the recurrent axon collateral network of the substantia nigra pars reticulata neurons in the rat. J. Neurosci. 23 (2003) 5247-5257
199. Mander A., McCausland M., Workman B., Flamer H., and Christophidis N. Fluoxetine induced dyskinesia. Aust. N. Z. J. Psychiatry 28 2 (1994) 328-330
200. Marazziti D., Betti L., Giannaccini G., Rossi A., Masala I., Baroni S., Cassano G., and Lucacchini A. Distribution of [3H]GR65630 binding in human brain postmortem. Neurochem. Res. 26 3 (2001) 187-190
201. Martin-Cora F.J., and Pazos A. Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. Br. J. Pharmacol. 141 1 (2004) 92-104
202. Martinez-Price D.L., and Geyer M.A. Subthalamic 5-HT1A and 5-HT1B receptor modulation of RU 24969-induced behavioral profile in rats. Pharmacol. Biochem. Behav. 71 4 (2002) 569-580
203. Matsubara K., Shimizu K., Suno M., Ogawa K., Awaya T., Yamada T., Noda T., Satomi M., Ohtaki K.-I., Chiba K., Tasaki Y., and Shiono H. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res. 1112 1 (2006) 126-133
204. Mayeux R. The "serotonin hypothesis" for depression in Parkinson's disease. Adv. Neurol. 53 (1990) 163-166
205. McQuade R., and Sharp T. Release of cerebral 5-hydroxytryptamine evoked by electrical stimulation of the dorsal and median raphe nuclei: effect of a neurotoxic amphetamine. Neuroscience 68 4 (1995) 1079-1088
206. Mehta A., Eberle-Wang K., and Chesselet M.-F. Increased m-CPP-induced oral dyskinesia after lesion of serotonergic neurons. Pharmacol. Biochem. Behav. 68 2 (2001) 347-353
207. Mendlin A., Martín F.J., and Jacobs B.L. Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain. Neuroscience 93 3 (1999) 897-905
208. Mengod G., Pompeiano M., Martinez-Mir M.I., and Palacios J.M. Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res. 524 1 (1990) 139-143
209. Mengod G., Vilaro M.T., Raurich A., Lopez-Gimenez J.F., Cortes R., and Palacios J.M. 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. Histochem. J. 28 11 (1996) 747-758
210. Middlemiss D.N., and Hutson P.H. The 5-HT1B receptors. Ann. N. Y. Acad. Sci. 600 (1990) 132-147 discussion 347-348
211. Mignon L., and Wolf W. Postsynaptic 5-HT1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl.) 163 1 (2002) 85-94
212. Mignon L., and Wolf W. Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease. Psychopharmacology (Berl.) 192 1 (2007) 49-59
213. Mignon L.J., and Wolf W.A. 8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 16 7 (2005) 699-703
214. Miller C.H., Fleischhacker W.W., Ehrmann H., and Kane J.M. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol. Bull. 26 3 (1990) 373-376
215. Miller K.M., Okun M.S., Fernandez H.F., Jacobson C.E., Rodriguez R.L., and Bowers D. Depression symptoms in movement disorders: comparing Parkinson's disease, dystonia, and essential tremor. Mov. Disord. 22 5 (2007) 666-672
216. Miquel M.C., Doucet E., Boni C., El Mestikawy S., Matthiessen L., Daval G., Verge D., and Hamon M. Central serotonin1A receptors: respective distributions of encoding mRNA, receptor protein and binding sites by in situ hybridization histochemistry, radioimmunohistochemistry and autoradiographic mapping in the rat brain. Neurochem. Int. 19 4 (1991) 453-465
217. Mitchell I.J., Sambrook M.A., and Crossman A.R. Subcortical changes in the regional uptake of [3H]-2-deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of a gamma-aminobutyric acid antagonist into the subthalamic nucleus. Brain 108 2 (1985) 405-422
218. Miyawaki E., Meah Y., and Koller W.C. Serotonin, dopamine, and motor effects in Parkinson's disease. Clin. Neuropharmacol. 20 4 (1997) 300-310
219. Molina-Holgado E., Dewar K.M., Descarries L., and Reader T.A. Altered dopamine and serotonin metabolism in the dopamine-denervated and serotonin-hyperinnervated neostriatum of adult rat after neonatal 6- hydroxydopamine. J. Pharmacol. Exp. Ther. 270 2 (1994) 713-721
220. Monsma Jr. F.J., Shen Y., Ward R.P., Hamblin M.W., and Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43 3 (1993) 320-327
221. 3 receptor subtype in the rat brain and spinal cord. J. Comp. Neurol. 402 3 (1998) 385-401
222. Moukhles H., Bosler O., Bolam J.P., Vallée A., Umbriaco D., Geffard M., and Doucet G. Quantitative and morphometric data indicate precise cellular interactions between serotonin terminals and postsynaptic targets in rat substantia nigra. Neuroscience 76 4 (1997) 1159-1171
223. Mrini A., Soucy J.-P., Lafaille F., Lemoine P., and Descarries L. Quantification of the serotonin hyperinnervation in adult rat neostriatum after neonatal 6-hydroxydopamine lesion of nigral dopamine neurons. Brain Res. 669 2 (1995) 303-308
224. Naidu P.S., and Kulkarni S.K. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur. J. Pharmacol. 428 1 (2001) 81-86
225. Naidu P.S., and Kulkarni S.K. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists. Eur. J. Pharmacol. 420 2-3 (2001) 113-117
226. Navailles S., De Deurwaerdère P., and Spampinato U. Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo. Biol. Psychiatry 59 6 (2006) 568-575
227. Nayak S.V., Ronde P., Spier A.D., Lummis S.C.R., and Nichols R.A. Calcium changes induced by presynaptic 5-hydroxytryptamine-3 serotonin receptors on isolated terminals from various regions of the rat brain. Neuroscience 91 1 (1999) 107-117
228. Neal-Beliveau B.S., Joyce J.N., and Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther. 265 1 (1993) 207-217
229. Nichols R.A., and Mollard P. Direct observation of serotonin 5-HT3 receptor-induced increases in calcium levels in individual brain nerve terminals. J. Neurochem. 67 2 (1996) 581-592
230. Nicholson S.L., and Brotchie J.M. 5-Hydroxytryptamine (5-HT, serotonin) and Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol. 9 Suppl 3 (2002) 1-6
231. Nishio H., Kohno Y., Fujii A., Negishi Y., Inoue A., and Nakata Y. 5-HT3 receptor blocking properties of the antiparkinsonian agent, talipexole. Gen. Pharmacol. 27 5 (1996) 779-785
232. Numan S., Lundgren K.H., Wright D.E., Herman J.P., and Seroogy K.B. Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res. Mol. Brain Res. 29 2 (1995) 391-396
233. O'Neill M.F., Heron-Maxwell C.L., and Shaw G. 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. Pharmacol. Biochem. Behav. 63 2 (1999) 237-243
234. Oberlander C., Demassey Y., Verdu A., Van de Velde D., and Bardelay C. Tolerance to the serotonin 5-HT1 agonist RU 24969 and effects on dopaminergic behaviour. Eur. J. Pharmacol. 139 2 (1987) 205-214
235. Oberlander C., Hunt P.F., Dumont C., and Boissier J.R. Dopamine independent rotational response to unilateral intranigral injection of serotonin. Life Sci. 28 23 (1981) 2595-2601
236. Okazawa H., Yamane F., Blier P., and Diksic M. Effects of acute and chronic administration of the serotonin1A agonist buspirone on serotonin synthesis in the rat brain. J. Neurochem. 72 5 (1999) 2022-2031
237. Oliver K.R., Kinsey A.M., Wainwright A., and Sirinathsinghji D.J. Localization of 5-ht(5A) receptor-like immunoreactivity in the rat brain. Brain Res. 867 1-2 (2000) 131-142
238. Olpe H.R., and Koella W.P. The response of striatal cells upon stimulation of the dorsal and median raphe nuclei. Brain Res. 122 2 (1977) 357-360
239. Pakhotin P., and Bracci E. Cholinergic interneurons control the excitatory input to the striatum. J. Neurosci. 27 2 (2007) 391-400
240. Park M.R., Gonzales-Vegas J.A., and Kitai S.T. Serotonergic excitation from dorsal raphe stimulation recorded intracellularly from rat caudate-putamen. Brain Res. 243 1 (1982) 49-58
241. Parker R.M.C., Barnes J.M., Ge J., Barber P.C., and Barnes N.M. Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J. Neurol. Sci. 144 1-2 (1996) 119-127
242. Pasqualetti M., Nardi I., Ladinsky H., Marazziti D., and Cassano G.B. Comparative anatomical distribution of serotonin 1A, 1D[alpha] and 2A receptor mRNAs in human brain postmorten. Brain Res. Mol. Brain Res. 39 1-2 (1996) 223-233
243. Paulus W., and Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. 50 6 (1991) 743-755
244. Pazos A., Cortes R., and Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 346 2 (1985) 231-249
245. Pazos A., and Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 346 2 (1985) 205-230
246. Pazos A., Probst A., and Palacios J.M. Serotonin receptors in the human brain. III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 21 1 (1987) 97-122
247. Pazos A., Probst A., and Palacios J.M. Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21 1 (1987) 123-139
248. Perkins M.N., and Stone T.W. Neuronal responses to 5-hydroxytryptamine and dorsal raphe stimulation within the globus pallidus of the rat. Exp. Neurol. 79 1 (1983) 118-129
249. Phelps P.E., Houser C.R., and Vaughn J.E. Immunocytochemical localization of choline acetyltransferase within the rat neostriatum: a correlated light and electron microscopic study of cholinergic neurons and synapses. J. Comp. Neurol. 238 3 (1985) 286-307
250. Pike V.W., McCarron J.A., Lammerstma A.A., Hume S.P., Poole K., Grasby P.M., Malizia A., Cliffe I.A., Fletcher A., and Bench C.J. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. Eur. J. Pharmacol. 283 1-3 (1995) R1-R3
251. Pineyro G., and Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 51 3 (1999) 533-591
252. Pires J.G., Bonikovski V., and Futuro-Neto H.A. Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Braz. J. Med. Biol. Res. 38 12 (2005) 1867-1872
253. Pompeiano M., Palacios J.M., and Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. 12 2 (1992) 440-453
254. Pompeiano M., Palacios J.M., and Mengod G. Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res. Mol. Brain Res. 23 1-2 (1994) 163-178
255. Porras G., Di Matteo V., Fracasso C., Lucas G., De Deurwaerdere P., Caccia S., Esposito E., and Spampinato U. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26 3 (2002) 311-324
256. Prinssen E.P., Koek W., and Kleven M.S. The effects of antipsychotics with 5-HT(2C) receptor affinity in behavioral assays selective for 5-HT(2C) receptor antagonist properties of compounds. Eur. J. Pharmacol. 388 1 (2000) 57-67
257. Queiroz C.M., and Frussa-Filho R. Effects of buspirone on an animal model of tardive dyskinesia. Prog. Neuropsychopharmacol. Biol. Psychiatry 23 8 (1999) 1405-1418
258. Querejeta E., Oviedo-Chavez A., Araujo-Alvarez J.M., Quinones-Cardenas A.R., and Delgado A. In vivo effects of local activation and blockade of 5-HT1B receptors on globus pallidus neuronal spiking. Brain Res. 1043 1-2 (2005) 186-194
259. Quirion R., and Richard J. Differential effects of selective lesions of cholinergic and dopaminergic neurons on serotonin-type 1 receptors in rat brain. Synapse 1 1 (1987) 124-130
260. Radja F., Descarries L., Dewar K.M., and Reader T.A. Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study. Brain Res. 606 2 (1993) 273-285
261. Rammes G., Eisensamer B., Ferrari U., Shapa M., Gimpl G., Gilling K., Parsons C., Riering K., Hapfelmeier G., Bondy B., Zieglgansberger W., Holsboer F., and Rupprecht R. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol. Psychiatry 9 9 (2004) 846-858
262. Rauser L., Savage J.E., Meltzer H.Y., and Roth B.L. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J. Pharmacol. Exp. Ther. 299 1 (2001) 83-89
263. Reavill C., Kettle A., Holland V., Riley G., and Blackburn T.P. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br. J. Pharmacol. 126 3 (1999) 572-574
264. Rees S., den Daas I., Foord S., Goodson S., Bull D., Kilpatrick G., and Lee M. Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 355 3 (1994) 242-246
265. Rempel N.L., Callaway C.W., and Geyer M.A. Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology 8 3 (1993) 201-211
266. Reynolds G.P. Receptor mechanisms in the treatment of schizophrenia. J. Psychopharmacol. (Oxford) 18 3 (2004) 340-345
267. Reynolds G.P., Mason S.L., Meldrum A., De Keczer S., Parnes H., Eglen R.M., and Wong E.H. 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. J. Pharmacol. 114 5 (1995) 993-998
268. Riad M., Mestikawy S.E., Verge D., Gozlan H., and Hamon M. Visualization and quantification of central 5-HT1A receptors with specific antibodies. Neurochem. Int. 19 4 (1991) 413-423
269. Rick C.E., Stanford I.M., and Lacey M.G. Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2C receptors. Neuroscience 69 3 (1995) 903-913
270. Ring H.A., and Serra-Mestre J. Neuropsychiatry of the basal ganglia. J. Neurol. Neurosurg. Psychiatry 72 (2002) 12-21
271. Roberts J.C., Reavill C., East S.Z., Harrison P.J., Patel S., Routledge C., and Leslie R.A. The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. Brain Res. 934 1 (2002) 49-57
272. 2A and N-methyl-D-aspartate receptors within single neurons in rat motor and limbic striatum. J. Comp. Neurol. 413 2 (1999) 219-231
273. Ronde P., and Nichols R.A. High calcium permeability of serotonin 5-HT3 receptors on presynaptic nerve terminals from rat striatum. J. Neurochem. 70 3 (1998) 1094-1103
274. Rosengarten H., Bartoszyk G.D., Quartermain D., and Lin Y. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 2 (2006) 273-279
275. Roth B.L., Ciaranello R.D., and Meltzer H.Y. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J. Pharmacol. Exp. Ther. 260 3 (1992) 1361-1365
276. Roth B.L., Meltzer H.Y., and Khan N. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. Adv. Pharmacol. 42 (1998) 482-485
277. Ruat M., Traiffort E., Arrang J.M., Tardivel-Lacombe J., Diaz J., Leurs R., and Schwartz J.C. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun. 193 1 (1993) 268-276
278. Ruat M., Traiffort E., Leurs R., Tardivel-Lacombe J., Diaz J., Arrang J.M., and Schwartz J.C. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. Proc. Natl. Acad. Sci. U.S.A. 90 18 (1993) 8547-8551
279. Rueter L.E., Tecott L.H., and Blier P. In vivo electrophysiological examination of 5-HT2 responses in 5-HT2C receptor mutant mice. Naunyn Schmiedebergs Arch. Pharmacol. 361 5 (2000) 484-491
280. Samad N., Khan A., Perveen T., Haider S., Abdul Haleem M., and Haleem D.J. Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia. Acta Neurobiol. Exp. 67 4 (2007) 389-397
281. Sari Y., Miquel M.C., Brisorgueil M.J., Ruiz G., Doucet E., Hamon M., and Verge D. Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies. Neuroscience 88 3 (1999) 899-915
282. Sawada M., Nagatsu T., Nagatsu I., Ito K., Iizuka R., Kondo T., and Narabayashi H. Tryptophan hydroxylase activity in the brains of controls and parkinsonian patients. J. Neural Transm. 62 1-2 (1985) 107-115
283. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., and Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275 2 (1983) 321-328
284. Schiller L., Jahkel M., Kretzschmar M., Brust P., and Oehler J. Autoradiographic analyses of 5-HT1A and 5-HT2A receptors after social isolation in mice. Brain Res. 980 2 (2003) 169-178
285. Scholtissen B., Verhey F.R., Steinbusch H.W., and Leentjens A.F. Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. J. Neural Transm. 113 1 (2006) 59-73
286. Schotte A., Janssen P.F., Megens A.A., and Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631 2 (1993) 191-202
287. Sethi K.D. Tremor. Curr. Opin. Neurol. 16 4 (2003) 481-485
288. Shen K.Z., and Johnson S.W. 5-HT inhibits synaptic transmission in rat subthalamic nucleus neurons in vitro. Neuroscience 151 4 (2008) 1029-1033
289. Shen K.Z., Kozell L.B., and Johnson S.W. Multiple conductances are modulated by 5-HT receptor subtypes in rat subthalamic nucleus neurons. Neuroscience 148 4 (2007) 996-1003
290. Shilliam C.S., and Dawson L.A. The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist. Neuropsychopharmacology 30 2 (2005) 372-380
291. Shink E., Bevan M.D., Bolam J.P., and Smith Y. The subthalamic nucleus and the external pallidum: two tightly interconnected structures that control the output of the basal ganglia in the monkey. Neuroscience 73 2 (1996) 335-357
292. Sian J., Gerlach M., Youdim M.B., and Riederer P. Parkinson's disease: a major hypokinetic basal ganglia disorder. J. Neural Transm. 106 5-6 (1999) 443-476
293. Simola N., Morelli M., and Carta A.R. The 6-hydroxydopamine model of Parkinson's disease. Neurotox. Res. 11 3-4 (2007) 151-167
294. Sivam S.P., Breese G.R., Krause J.E., Napier T.C., Mueller R.A., and Hong J.S. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression. J. Neurochem. 49 5 (1987) 1623-1633
295. Smith I.D., and Grace A.A. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse 12 4 (1992) 287-303
296. Stachowiak M.K., Bruno J.P., Snyder A.M., Stricker E.M., and Zigmond M.J. Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Res. 291 1 (1984) 164-167
297. Stanford I.M., Kantaria M.A., Chahal H.S., Loucif K.C., and Wilson C.L. 5-Hydroxytryptamine induced excitation and inhibition in the subthalamic nucleus: action at 5-HT(2C), 5-HT(4) and 5-HT(1A) receptors. Neuropharmacology 49 8 (2005) 1228-1234
298. Stanford I.M., and Lacey M.G. Differential actions of serotonin, mediated by 5-HT1B and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in vitro. J. Neurosci. 16 23 (1996) 7566-7573
299. Stefani, A., Fedele, E., Mazzone, P., Galati, S., Tropepi, P. and Stanzione, P. (2006) In vivo microdialysis in parkinsonian patients undergoing stereotactic neurosurgery: key insights on DBS mechanisms of actions. In: Valentini, V., Di Chiara, G. (Eds.), Proceedings of the 11th International Conference of In Vivo Methods, University of Cagliari, Sardinia, Italy, pp. 74-76.
300. Stefani A., Surmeier D.J., and Kitai S.T. Serotonin enhances excitability in neostriatal neurons by reducing voltage-dependent potassium currents. Brain Res. 529 1-2 (1990) 354-357
301. Steffensen S.C., Svingos A.L., Pickel V.M., and Henriksen S.J. Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J. Neurosci. 18 19 (1998) 8003-8015
302. Steinbusch H.W. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 6 4 (1981) 557-618
303. Steward L.J., Bufton K.E., Hopkins P.C., Davies W.E., and Barnes N.M. Reduced levels of 5-HT3 receptor recognition sites in the putamen of patients with Huntington's disease. Eur. J. Pharmacol. 242 2 (1993) 137-143
304. Sturman M.M., Vaillancourt D.E., Metman L.V., Bakay R.A., and Corcos D.M. Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease. Brain 127 Pt 9 (2004) 2131-2143
305. Tarsy D., and Baldessarini R.J. Tardive dyskinesia. Annu. Rev. Med. 35 (1984) 605-623
306. Tauscher J., Kapur S., Verhoeff N.P., Hussey D.F., Daskalakis Z.J., Tauscher-Wisniewski S., Wilson A.A., Houle S., Kasper S., and Zipursky R.B. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch. Gen. Psychiatry 59 6 (2002) 514-520
307. Tepper J.M., and Bolam J.P. Functional diversity and specificity of neostriatal interneurons. Curr. Opin. Neurobiol. 14 6 (2004) 685-692
308. Trevitt J., Atherton A., Aberman J., and Salamone J.D. Effects of subchronic administration of clozapine, thioridazine and haloperidol on tests related to extrapyramidal motor function in the rat. Psychopharmacology (Berl.) 137 1 (1998) 61-66
309. Trevitt J.T., Lyons M., Aberman J., Carriero D., Finn M., and Salamone J.D. Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function. Psychopharmacology (Berl.) 132 1 (1997) 74-81
310. Twarog B.M., and Page I.H. Serotonin content of some mammalian tissues and urine and a method for its determination. Am. J. Physiol. 175 1 (1953) 157-161
311. Ullmer C., Engels P., Abdel'Al S., and Lubbert H. Distribution of 5-HT4 receptor mRNA in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 354 2 (1996) 210-212
312. Utter A.A., and Basso M.A. The basal ganglia: an overview of circuits and function. Neurosci. Biobehav. Rev. 32 3 (2008) 333-342
313. Van Bockstaele E.J., Biswas A., and Pickel V.M. Topography of serotonin neurons in the dorsal raphe nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens. Brain Res. 624 1-2 (1993) 188-198
314. Van Bockstaele E.J., Cestari D.M., and Pickel V.M. Synaptic structure and connectivity of serotonin terminals in the ventral tegmental area: potential sites for modulation of mesolimbic dopamine neurons. Brain Res. 647 2 (1994) 307-322
315. Van Bockstaele E.J., and Pickel V.M. GABA-containing neurons in the ventral tegmental area project to the nucleus accumbens in rat brain. Brain Res. 682 1-2 (1995) 215-221
316. Vandermaelen C.P., Bonduki A.C., and Kitai S.T. Excitation of caudate-putamen neurons following stimulation of the dorsal raphe nucleus in the rat. Brain Res. 175 2 (1979) 356-361
317. Varnas K., Hall H., Bonaventure P., and Sedvall G. Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743. Brain Res. 915 1 (2001) 47-57
318. Varnas K., Hurd Y.L., and Hall H. Regional expression of 5-HT1B receptor mRNA in the human brain. Synapse 56 1 (2005) 21-28
319. Varnas K., Thomas D.R., Tupala E., Tiihonen J., and Hall H. Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using [3H]SB-269970. Neurosci. Lett. 367 3 (2004) 313-316
320. Veazey C., Aki S.O., Cook K.F., Lai E.C., and Kunik M.E. Prevalence and treatment of depression in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 17 3 (2005) 310-323
321. Verge D., Daval G., Marcinkiewicz M., Patey A., el Mestikawy S., Gozlan H., and Hamon M. Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J. Neurosci. 6 12 (1986) 3474-3482
322. Vilaro M.T., Cortes R., Gerald C., Branchek T.A., Palacios J.M., and Mengod G. Localization of 5-HT4 receptor mRNA in rat brain by in situ hybridization histochemistry. Brain Res. Mol. Brain Res. 43 1-2 (1996) 356-360
323. Vilaro M.T., Cortes R., and Mengod G. Serotonin 5-HT4 receptors and their mRNAs in rat and guinea pig brain: distribution and effects of neurotoxic lesions. J. Comp. Neurol. 484 4 (2005) 418-439
324. Waddington J.L., Molloy A.G., O'Boyle K.M., and Mashurano M. Motor consequences of D-1 dopamine receptor stimulation and blockade. Clin. Neuropharmacol. 9 4 (1986) 20-22
325. Wadenberg M.L. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci. Biobehav. Rev. 20 2 (1996) 325-339
326. Waeber C., Dietl M.M., Hoyer D., and Palacios J.M. 5.HT1 receptors in the vertebrate brain. Regional distribution examined by autoradiography. Naunyn Schmiedebergs Arch. Pharmacol. 340 5 (1989) 486-494
327. Waeber C., Schoeffter P., Hoyer D., and Palacios J.M. The serotonin 5-HT1D receptor: a progress review. Neurochem. Res. 15 6 (1990) 567-582
328. Waeber C., Sebben M., Nieoullon A., Bockaert J., and Dumuis A. Regional distribution and ontogeny of 5-HT4 binding sites in rodent brain. Neuropharmacology 33 3-4 (1994) 527-541
329. Waeber C., Zhang L.A., and Palacios J.M. 5-HT1D receptors in the guinea pig brain: pre- and postsynaptic localizations in the striatonigral pathway. Brain Res. 528 2 (1990) 197-206
330. Ward R.P., and Dorsa D.M. Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J. Comp. Neurol. 370 3 (1996) 405-414
331. Ward R.P., Hamblin M.W., Lachowicz J.E., Hoffman B.J., Sibley D.R., and Dorsa D.M. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience 64 4 (1995) 1105-1111
332. Weiner D.M., Vanover K.E., Brann M.R., Meltzer H.Y., and Davis R.E. Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics. Curr. Opin. Investig. Drugs 4 7 (2003) 815-819
333. Wesolowska A. In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors. Pol. J. Pharmacol. 54 4 (2002) 327-341
334. Wilms K., Vierig G., and Davidowa H. Interactive effects of cholecystokinin-8S and various serotonin receptor agonists on the firing activity of neostriatal neuronesin rats. Neuropeptides 35 5-6 (2001) 257-270
335. Wolf W.A., Bieganski G.J., Guillen V., and Mignon L. Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology (Berl.) 182 1 (2005) 84-94
336. Wright D.E., Seroogy K.B., Lundgren K.H., Davis B.M., and Jennes L. Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain. J. Comp. Neurol. 351 3 (1995) 357-373
337. Xiang Z., Wang L., and Kitai S.T. Modulation of spontaneous firing in rat subthalamic neurons by 5-HT receptor subtypes. J. Neurophysiol. 93 3 (2005) 1145-1157
338. Yakel J.L., Trussell L.O., and Jackson M.B. Three serotonin responses in cultured mouse hippocampal and striatal neurons. J. Neurosci. 8 4 (1988) 1273-1285
339. Yoshioka M., Matsumoto M., Togashi H., and Mori K. Central distribution and function of 5-ht6 receptor subtype in the rat brain. Ann. N. Y. Acad. Sci. 861 1 (1998) 244
340. Zhang Q.J., Gao R., Liu J., Liu Y.P., and Wang S. Changes in the firing activity of serotonergic neurons in the dorsal raphe nucleus in a rat model of Parkinsonos disease. Sheng Li Xue Bao 59 2 (2007) 183-189
341. Zhang X., Andren P.E., Greengard P., and Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 105 6 (2008) 2163-2168
342. Zhang X., Andren P.E., and Svenningsson P. Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Physiol. Behav. 92 1-2 (2007) 29-33
343. Zhou F.C., Bledsoe S., and Murphy J. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res. 556 1 (1991) 108-116
344. Zhou F.M., Wilson C.J., and Dani J.A. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J. Neurobiol. 53 4 (2002) 590-605